Researchers conducted a network meta-analysis (NMA) to compare tirzepatide and semaglutide in patients with type 2 diabetes. They included multiple randomized controlled trials. This approach ranks treatments by pooling direct and indirect evidence.
Weight loss outcomes stand out clearly.
Tirzepatide shows superior results. For example, it achieves greater percentage weight reduction. Studies report a mean difference of about 6.1% in favor of tirzepatide over semaglutide. Absolute weight loss also favors tirzepatide, with differences around 4-5 kg or more in various analyses. Additionally, tirzepatide reduces BMI and waist circumference more effectively. Patients often lose 10-15% or more body weight with tirzepatide, compared to lower amounts with semaglutide.
Remission outcomes improve with both drugs. Tirzepatide increases the likelihood of type 2 diabetes remission. Odds ratios reach around 15-16 in some network analyses. Semaglutide also promotes remission, with odds around 12. However, tirzepatide frequently ranks higher. It helps restore normoglycemia in prediabetes cases more robustly.
Cardiovascular outcomes demonstrate benefits for both. Semaglutide reduces major adverse cardiovascular events (MACE) and all-cause mortality in several studies. It lowers risks significantly compared to controls. Tirzepatide reduces heart failure hospitalizations. Some real-world data show comparable cardiovascular risk reduction between the two. Head-to-head comparisons often find similar overall CV protection, though long-term dedicated trials continue.
Renal outcomes appear promising. Tirzepatide slows eGFR decline and reduces albuminuria more than some comparators. It ameliorates kidney parameter changes in high-risk patients. Semaglutide also protects kidneys, as seen in trials like FLOW. Network evidence suggests tirzepatide may offer additional advantages in albuminuria reduction, but direct head-to-head renal outcome trials remain needed.
Overall, tirzepatide outperforms semaglutide in weight loss, glycemic control, and diabetes remission. Both provide strong cardiorenal protection. Gastrointestinal side effects occur with both, but they remain mostly mild to moderate.